NCT00548418View on ClinicalTrials.gov

Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Cervical Cancer
Interventions
DRUG

Topotecan

DRUG

Cisplatin

DRUG

Bevacizumab

Trial Locations (3)

63110

Washington University School of Medicine, St Louis

Unknown

Duke Cancer Institute, Durham

The Ohio State University College of Medicine, Columbus

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT00548418 - Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer | Biotech Hunter | Biotech Hunter